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Serum samples from 317 patients with severe acute
respiratory syndrome (SARS) were tested for the nucleo-
capsid (N) protein of SARS-associated coronavirus, with
sensitivities of 94% and 78% for the first 5 days and 6–10
days after onset, respectively. The specificity was 99.9%. N
protein can be used as an early diagnostic maker for
SARS.
E
arly laboratory diagnosis of the severe acute respirato-
ry syndrome–associated coronavirus (SARS-CoV) is
one step in preventing recurrence of a global outbreak. The
availability of the complete genomic sequence of SARS-
CoV has facilitated the development of a variety of diag-
nostic tests for SARS (1). Reverse transcription–
polymerase chain reaction (RT-PCR) has been used as a
rapid diagnostic test in most of the research centers during
the last epidemic (2–6). However, early diagnosis of SARS
remains a problem for nonresearch laboratories with little
experience in molecular testing. We have developed an
antigen-capture enzyme-linked immunosorbent assay
(ELISA) based on monoclonal antibodies against the
nucleocapsid (N) protein of SARS-CoV (7), a predominant
antigen produced in the infected cell-culture filtrate. High
levels of circulating N protein can be detected in the serum
samples of patients with SARS. We attempt to demonstrate
the temporal profile of the N protein and antibodies in
serum samples from a large cohort of patients with SARS
during the acute and convalescent phases of the disease.
Our findings suggest that detecting N protein in serum can
be used as an early diagnostic marker for SARS.
The Study
During the 2003 SARS epidemic in Guangzhou, 420
serum specimens were collected from 317 patients 1–90
days after the onset of symptoms. The condition of all
patients was diagnosed according to the World Health
Organization criteria and confirmed by seroconversion or
a fourfold increase in antibody titer against SARS-CoV by
means of immunofluorescent testing. The N protein–cap-
ture ELISA was performed (7). Briefly, 100 µL of serum
was added to the wells of a microtiter plate coated with a
mixture of three anti-N protein monoclonal antibodies, and
the plates were incubated at 37°C for 60 min. After the
plates were washed, 100 µLof anti-N rabbit antiserum was
added to the wells, and the plates were incubated at 37°C
for 60 min. The wells were washed again and incubated for
1 h at 37°C with 100 µL of peroxidase-conjugated goat
anti-rabbit immunoglobulin (Ig)G . After the plates were
washed, 100 µL of tetramethylbenzidine solution was
added to each well. The experiments involving the use of
serum samples from patients with SARS were performed
within the safety cabinet of a biosafety level 2 laboratory. 
The results for the 420 serum specimens tested by the
N protein–capture ELISA are shown in Figure 1. The N
protein could be detected as early as day 1 and until day
18. In the 146 serum samples positive for N protein, the
optical density (OD) value was highly variable from one
sample to another on the same day. The sensitivity of
detection was 94% (80 of 85 patients) with blood samples
taken during the first 5 days and 78% (47 of 60 patients)
for samples taken 6–10 days after onset of symptoms. The
detection rate of N protein decreased to 27% on days
11–20 after onset of symptoms. Serum N protein was
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Figure 1. N protein detection in 420 serum samples from 317
patients with severe acute respiratory syndrome (SARS). Data
represent the optical density at 450 nm (OD450) of undiluted serum
samples. To establish the normal range of the N protein–capture
enzyme-linked immunosorbent assay, serum specimens from 400
healthy blood donors were analyzed. The mean OD450 for these
specimens, as determined by the assay, was 0.078, with a stan-
dard deviation of 0.023. The cutoff OD450 of the assay was then
calculated as follows: cutoff = mean of OD450 from 400 normal
serum samples + 5 x standard deviations = 0.19. Solid line repre-
sents cutoff value. The result was considered positive if a sample
yielded OD450 above the cutoff. never detected beyond day 21. Using the same panel of the
patient serum samples, we measured the N protein–specif-
ic IgG (SARS-CoV N-IgG) and SARS-CoV–specific IgG
(SARS-CoV IgG) in serum samples by indirect ELISA,
which progressively increased from day 7 onward
(Figure 2). With the appearance of antibodies, the N pro-
tein detection rate decreased from day 10 after the onset of
symptoms. However, from day 7 to day 18, a high level of
N protein was still detectable in the serum samples from 11
patients with a mean of OD values of 1.65 when the
SARS-CoV N-IgG had already increased to a level with a
mean OD value of 1.18. 
Serum samples from patients collected 4 years previ-
ously were used as negative controls. Patients thought to
have cases of SARS on admission and later found to be
uninfected by serologic testing, and healthcare workers
who had close contact with SARS patients were tested for
circulating N protein. Of the serum samples from non-
SARS patients collected 4 years previously (n = 400), only
one was weakly positive for N protein (OD = 0.288). We
tested a total of 110 acute-phase serum samples from 105
patients, initially considered to have suspected SARS and
later proven to be negative for SARS-CoV by serologic
testing of convalescent-phase serum samples taken >28
days after onset of symptoms, and 315 serum samples
from healthcare workers. All were negative for the N pro-
tein by capture ELISA. This finding resulted in a test
specificity of 99.9% (1 of 825).
Conclusions 
Our results suggest that N protein in the serum samples
of SARS patients can be detected as early as day 1 after
disease onset. Although the level of circulating N protein
was highly variable from one person to another from day 1
to day 18, development of SARS-CoV N-IgG appears not
to be affected by N protein during the acute phase of the
infection, 7 days after the onset of symptoms. The positive
detection rate of N protein in serum samples within the
first 10 days of infection is higher than that detected by RT-
PCR (8,9). Furthermore, the variation in the reported sen-
sitivity and specificity of RT-PCR may be related to the
lack of standardization of the assay and the specimen col-
lection (6). Therefore, this viral antigen-capture ELISA
may have greater sensitivity, specificity, and ease and reli-
ability of in-use performance than the nucleic acid ampli-
fication assay. Further comparative studies with nucleic
acid amplification tests should be undertaken at clinical
laboratories serving acute-care hospitals where rapid
SARS diagnosis is vital.
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